A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia

References

• Cosnes J, Gower Rousseau C, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140(6):1785-94
   PubMed Web of Science ®Google Scholar
• Burisch J, Jess T, Martinato M, Lakatos PL. The burden of inflammatory bowel disease in Europe. J Crohn’s & colitis 2013;7(4):322-37
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Bjerrum JT, Seidelin JB, et al. Biological treatment of Crohn’s disease. Dig Dis 2012;30(3):121-33
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Available from: www.ema.europa.eu/ema/ [Last accessed: 08 September 2014]
   Google Scholar
• Rencz F, Pentek M, Bortlik M, et al. Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe. World j gastroenterol 2015;21(6):1728-37
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Biologic drugs for the treatment of inflammatory disease in rheumatology, dermatology and gastroenterology. Commissioning guide. 2012. Available from: www.nice.org.uk/proxy/?sourceUrl=http%3a%2f%2fwww.nice.org.uk%2fmedia%2fF95%2f42%2fUpdateTA247AndPsoriasisCG.pdf [Last accessed 03 August 2015]
   Google Scholar
• Tothfalusi L, Endrenyi L, Chow SC. Statistical and regulatory considerations in assessments of interchangeability of biological drug products. Eur J Health Econ 2014;15(1):S5-11
   Google Scholar
• Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73(3):492-509
   PubMed Web of Science ®Google Scholar
• Danese S, Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013;7(7):586-9
   PubMed Web of Science ®Google Scholar
• Mularczyk A, Gonciarz M, Bartnik W, et al. Biosimilar medicines - their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology. Prz Gastroenterol 2014;9(1):1-3
   PubMedGoogle Scholar
• Gecse K, Farkas K, Lovasz B, et al. P314 Biosimilar infliximab in inflammatory bowel diseases: first interim Results from a prospective nationwide observational cohort. J Crohn’s Colitis 2015;9(1):S234
   Google Scholar
• Jarzebicka D, Banaszkiewicz A, Plocek A, et al. P295 Preliminary assessment of efficacy and safety of switching between originator and biosimilar infliximab in paediatric Crohn disease patients. J Crohn’s Colitis 2015;9(1):S224
   Google Scholar
• Sieczkowska J, Banaszkiewicz A, Plocek A, et al. P430 Assessment of safety and efficacy of biosimilar infliximab in children with Crohn disease: a preliminary report. J Crohn’s Colitis 2015;9(1):S295
   Google Scholar
• Yoon Suk J, Park JI, Kim YH, et al. P540 Efficacy and safety of infliximab’s biosimilar (REMSIMA) for IBD. J Crohn’s Colitis 2015;91:S349-50
   Google Scholar
• Brodszky V, Baji P, Balogh O, Pentek M. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ 2014;15(1):S65-71
   Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 2014;17(1):5-14
   PubMed Web of Science ®Google Scholar
• Laki J, Monok G, Palosi M, Gajdacsi JZ. Economical aspect of biological therapy in inflammatory conditions in Hungary. Expert Opin Biol Ther 2013;13(3):327-37
   PubMed Web of Science ®Google Scholar
• Department of Medical Expertise Clinical Auditing and Analysis NHIFA. Biological therapy 2006-2010-Analysis 2012
   Google Scholar
• Koncz T, Pentek M, Brodszky V, et al. Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opin Biol Ther 2010;10(9):1367-78
   PubMed Web of Science ®Google Scholar
• Orlewska E, Gulacsi L. Budget-impact analyses: a critical review of published studies. Pharmacoeconomics 2009;27(10):807-27
   PubMed Web of Science ®Google Scholar
• van de Vooren K, Duranti S, Curto A, Garattini L. A critical systematic review of budget impact analyses on drugs in the EU countries. Appl Health Econ Health Policy 2014;12(1):33-40
   PubMedGoogle Scholar
• Bakhshai J, Bleu-Laine R, Jung M, et al. The cost effectiveness and budget impact of natalizumab for formulary inclusion. J Med Econ 2010;13(1):63-9
   PubMedGoogle Scholar
• Dretzke J, Edlin R, Round J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-alpha) inhibitors, adalimumab and infliximab, for Crohn’s disease. Health Technol Assess 2011;15(6):1-244
   PubMed Web of Science ®Google Scholar
• Kim J, An Hong J, Kudrin A. P137. 5 year budget impact analysis of CT-P13 (Infliximab) for the treatment of Crohn’s Disease in UK, Italy and France. J Crohn’s Colitis 2015;9(1):S144-5
   Google Scholar
• Mandel MD, Balint A, Lovasz BD, et al. Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. Eur J Health Econ 2014;15(1):S121-8
   Google Scholar
• Gulacsi L, Rotar AM, Niewada M, et al. Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. Eur J Health Econ 2014;15(1):13-25
   Web of Science ®Google Scholar
• Gulacsi L, Pentek M. HTA in Central and Eastern European countries; the. 2001: a space odyssey and efficiency gain. Eur J Health Econ 2014;15(7):675-80
   PubMed Web of Science ®Google Scholar